CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction Frailty Is Intertwined With Heart Failure: Mechanisms, Prevalence, Prognosis, Assessment, and Management Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial Mechanical circulatory support devices in advanced heart failure: 2020 and beyond Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"
|<<... 5 6 7 8 9 10 11 ...>>|

Expert OpinionDec 21, 2018

JOURNAL：ACC Article Link

Drug-Drug Interactions of Common Cardiac Medications and Chemotherapeutic Agents

S Zukkoor, V Thohan. Keywords: Drug-Drug Interaction; Cardiac Medication; chemotherapeutic agents

ABSTRACT

As the field of cardio-oncology evolves, the focus of treatment has shifted from reactive to proactive care. Prevention of cancer therapy-related cardiac dysfunction through optimization of cardiac risk factors and periodic surveillance, as well as minimal interruption of cancer treatment, is the emphasis of modern treatment paradigms.1 Cardio-protection frequently involves the initiation of cardiac medications, including certain beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs), and statins. Similarly, patients with pre-existing cardiac diseases are often prescribed a number of medications, such as anticoagulants and antiarrhythmics, that have potential and real interactions with a variety of chemotherapies. Because the therapeutic window for most chemotherapies is narrow, special attention should be given to these drug-drug interactions that may increase or decrease chemotherapeutic efficacy or predispose patients to serious unintended side effects. These drug-drug interactions are quite prevalent in the cancer population; one study determined that 16% of patients receiving oral anticancer drugs had at least one major drug-drug interaction that could cause harmful adverse effects.2 Health care providers should be aware of potential drug-drug interactions and mitigate risks as they manage cardiovascular health in the context of cancer treatment. In the following review of drug-drug interactions involving chemotherapeutic and common cardiac medications, areas of focus include typical pharmacokinetic (PK) and pharmacodynamic (PD) interactions, antithrombotics, and QT prolongation.



>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top